Prostate Cancer Presenting With an Unusual Presentation of Rectal Pain and Bleeding

An unusual presentation of advanced prostate cancer in a 56-year old Nigerian

African Journal of Urology ◽

10.1016/j.afju.2016.08.001 ◽

2017 ◽

Vol 23 (2) ◽

pp. 139-143

Author(s):

P.O. Areo ◽

A.E. Omonisi ◽

P.T. Adegun ◽

J.A. Omotayo ◽

S.A. Dada ◽

...

Keyword(s):

Prostate Cancer ◽

Advanced Prostate Cancer ◽

Unusual Presentation

Download Full-text

Unusual presentation of advanced prostate cancer in a black population of South-Western Nigeria

Pan African Medical Journal ◽

10.11604/pamj.2019.32.15.14417 ◽

2019 ◽

Vol 32 ◽

Author(s):

Abdulkadir Salako ◽

Tajudeen Badmus ◽

Akinwunmi Komolafe ◽

Rotimi David ◽

Martin Igbokwe ◽

...

Keyword(s):

Prostate Cancer ◽

Advanced Prostate Cancer ◽

Black Population ◽

Unusual Presentation

Download Full-text

A set of nomograms predicting acute gastrointestinal syndrome after prostate cancer conformal radiation

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.15555 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 15555-15555

Author(s):

R. Valdagni ◽

T. Rancati ◽

C. Fiorino ◽

G. Fellin ◽

L. Vera Righi ◽

...

Keyword(s):

Prostate Cancer ◽

Fecal Incontinence ◽

Protective Factor ◽

Drug Prescription ◽

Continuous Variable ◽

Seminal Vesicles ◽

Severe Bleeding ◽

Rectal Pain ◽

Rectal Dose ◽

Gi Symptoms

15555 Background: To predict acute toxicities (tox) of the gastrointestinal syndrome (SOMA LENT) in prostate cancer (PCa) patients (pts) undergoing 3D-CRT using a tool (nomogram) with clinical as well as dosimetric variables which has proved to be significant in the AIROPROS 01–02 trial. Methods: Acute rectal tox was scored in 1,132 pts using a 10 item self assessed questionnaire (QST) describing radio-induced GI symptoms profiles for bowel frequency, tenesmus, fecal continence, rectal pain and bleeding. The correlation between hormonal therapy (HT), drug prescription, diabetes or hypertension, pelvic node or seminal vesicles irradiation, mean rectal dose, DVH constraints and rectal tox was investigated by uni- and multivariate (MVA) logistic analyses. MVA results were used the R-project software to create nomograms predicting the symptoms of the acute GI syndrome. Results: 4/10 items of the QST are reported: moderate/severe bleeding, increased bowel frequency, moderate/severe bowel urgency and severe fecal incontinence. Bleeding is related to haemorrhoids (OR=1.9), HT (protective factor, OR=0.78) and mean rectal dose (continuous variable (cv), OR=1.024). Bowel frequency is related to seminal vesicles irradiation (OR=2.8) and V60 (cv, OR=1.024), while bowel urgency is correlated to seminal vesicles irradiation (OR=3.3) and mean rectal dose (cv, OR=1.027). Fecal incontinence depends on seminal vesicles irradiation (OR=4.6) and V70 (cv, OR=1.029). MVA results were used to create a set of nomograms. Conclusions: The combined effect of several independent, prognostically valuable variables for a specific disease can be expressed using nomograms. They can evaluate clinical and technical parameters of the single pt and offer clinicians a tailored probability of a specific outcome. To our best knowledge, this work presents the first set of nomograms available in the literature specific symptoms of the GI syndrome. The prediction capability of these tools will be validated on a independent set of patients. This work was partly supported by Fondazione I. Monzino, Milan No significant financial relationships to disclose.

Download Full-text

Rectal toxicity results for patients treated with HDR brachytherapy as monotherapy versus dose-escalated external beam radiotherapy for localized prostate cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.7_suppl.5 ◽

2019 ◽

Vol 37 (7_suppl) ◽

pp. 5-5

Author(s):

Jacob Samuel Parzen ◽

Hong Ye ◽

Gary S. Gustafson ◽

Alvaro Martinez ◽

Evelyn Sebastian ◽

...

Keyword(s):

Prostate Cancer ◽

Rectal Bleeding ◽

External Beam Radiotherapy ◽

High Dose Rate ◽

Localized Prostate Cancer ◽

High Dose ◽

External Beam ◽

Hdr Brachytherapy ◽

Rectal Toxicity ◽

Rectal Pain

5 Background: We present a large retrospective analysis comparing rectal toxicity following high dose rate (HDR) brachytherapy as monotherapy relative to dose-escalated external beam radiotherapy (EBRT) for patients with localized prostate cancer. Methods: 2683 patients treated with HDR or EBRT between 1994 and 2017 were included. 545 (20.3%) received HDR and 2138 (79.7%) EBRT. HDR fractionation was 38 Gy/4 fractions (n=321), 24 Gy/2 (n=96), or 27 Gy/2 (n=128). EBRT patients received a median dose of 75.6 Gy in 1.8 Gy fractions [range 70.2-82.8 Gy], using either 3D conformal or intensity modulated radiotherapy (IMRT). All EBRT patients underwent 3D image guidance via an off-line adaptive process. Treatment was directed to prostate only (n=780) or prostate and seminal vesicles (n=1351). No nodal therapy was given. Target volume for HDR patients included the prostate with no expansion. Acute and chronic gastrointestinal (GI) toxicity was defined as occurring ≤ 6 and > 6 months, respectively, after radiotherapy and was graded per CTCAE version 3.0. Toxicity variables were analyzed with χ2 test. Results: Median follow-up was 7.5 years (7.4 years for EBRT and 7.9 years for HDR). 69.1% of EBRT patients received IMRT with the remainder treated using 3D conformal technique. Compared to EBRT, HDR was associated with decreased rates of acute grade ≥ 2 diarrhea (0.7% vs. 4.5%, p < 0.001), rectal pain/tenesmus (0.6% vs. 7.9%, p < 0.001), and rectal bleeding (0% vs. 1.6%, p=0.001). Rates of chronic grade ≥ 2 rectal bleeding (1.3% vs. 8.7%, p < 0.001) and radiation proctitis (0.9% vs. 3.3%, p=0.001) favored HDR over EBRT. Rates of any chronic rectal toxicity grade ≥ 2 were 2.4% vs. 10.5% (p < 0.001) for HDR vs. EBRT, respectively. For the 1478 EBRT patients treated with IMRT, acute and chronic rates of any grade ≥ 2GI toxicity were 4.2% and 5.6%, respectively, compared to 1.5% (p=0.002) and 2.4% (p=0.002), respectively, for HDR patients. Conclusions: In appropriately selected patients with localized prostate cancer undergoing definitive radiation therapy, HDR brachytherapy as monotherapy is an effective strategy for reducing acute and chronic rectal toxicity.

Download Full-text

An unusual presentation of prostate cancer posing a diagnostic dilemma: A case report

Urology Case Reports ◽

10.1016/j.eucr.2020.101432 ◽

2021 ◽

Vol 34 ◽

pp. 101432

Author(s):

Nina Al-Saadi ◽

Safa Al-Musawi ◽

Yousuf Khan ◽

Daben Dawam

Keyword(s):

Prostate Cancer ◽

Case Report ◽

Unusual Presentation ◽

Diagnostic Dilemma

Download Full-text

Stereotactic robotic radiosurgery for localized prostate cancer: Initial evaluation of acute toxicities

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e16006 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e16006-e16006

Author(s):

L. E. Ponsky ◽

C. Lillibridge ◽

J. Brindle ◽

Y. Zhang ◽

B. Wessels ◽

...

Keyword(s):

Prostate Cancer ◽

Early Stage ◽

Transrectal Ultrasound ◽

Target Volume ◽

Post Treatment ◽

Intermediate Risk ◽

Rectal Pain ◽

Robotic Radiosurgery ◽

Risk Prostate Cancer ◽

Pre Treatment

e16006 Background: We evaluated the initial acute toxicities experienced by patients treated with cyberknife fractionated radiosurgery for low and low-intermediate risk prostate cancer. Methods: Twenty-two patients with low or low-intermediate risk prostate cancer (T2a, GG 3+3=6 or 3+4=7, PSA <10) were enrolled prospectively on an IRB approved protocol and treated the planning target volume (PTV)(prostate+5mm margin) with cyberknife fractionated radiosurgery to a dose of 36.25 Gy in 5 fractions (7.25Gy/fraction). The target volume included the prostate and seminal vesicles. PSA values, AUA symptom scores (AUA SS), and NCI CTC acute toxicities were analyzed prior to radiosurgery and at 1 month (N=16), 3 months (N=12) and 6 months (N=5)post-treatment. Results: Patients treated on study included 12 with GG 3+3=6 cancer and 10 with GG 3+4=7 cancer. Mean patient age was 66 years old (range 49–79). Mean pre-treatment PSA was 5.29 (range 0.64–9.36) declining to 3.44 (range 0.00–10.43) at 1 month post treatment, 1.99 (range 0.31–3.99) at 3 months post-treatment and 2.08 (1.05–3.13) at 6 months post-treatment. Mean pre-treatment AUA SS was 7 (range 0.–18) increasing to 12 (range 2–29) at 1 month post treatment, decreasing to 8 (range 2–17) at 3 months post-treatment and 11 (3–17). There were 5 grade 1 acute toxicities including (diarrhea, fatigue, mild urinary frequency, hemorrhoid and a rash) and 7 grade 2 toxicities including (bladder spasms, painful urinary, bowel irregularity, rectal pain, urethritis and numbness in the upper thigh), all grade 1 and 2 toxicities resolved within three months of treatment. The one patient with grade 2 thigh numbness was not thought to be study related toxicity. Two patients developed grade 3 toxicity. One developed bacteremia after the transrectal ultrasound guided placement of the fiducials, the infection completely resolved after treatment with antibiotics. One patient on Coumadin developed hematuria which resolved with conservative management. Conclusions: Cyberknife fractionated radiosurgery for patients with early stage prostate cancer appears to be safe on our early initial assessment.Continued evaluation and longer follow-up ongoing. [Table: see text]

Download Full-text